Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra 16:35:28 09/05/2024 BST After market 20:16:19
28.03 EUR -1.58% Intraday chart for Fresenius SE & Co. KGaA 28.05 +0.07%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
FRESENIUS SE : Deutsche Bank keeps its Buy rating ZD
Health Care Slips as Defensive Investors Rotate to Utilities - Health Care Roundup DJ
Home REIT cuts borrowings, Genflow shares restored AN
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading MT
Fresenius becomes more optimistic thanks to subsidiary Kabi - exit from Vamed DP
UBS rates Fresenius SE as 'Buy' - Target 34 euros DP
Dpa-AFX Overview: COMPANIES from 08.05.2024 - 15:15 DP
FRESENIUS SE : Berenberg reiterates its Buy rating ZD
FRESENIUS SE : Buy rating from UBS ZD
FRESENIUS SE : Warburg Research reaffirms its Buy rating ZD
FRESENIUS SE : Barclays maintains a Buy rating ZD
Transcript : Fresenius SE & Co. KGaA, Q1 2024 Earnings Call, May 08, 2024
FRESENIUS SE : Gets a Neutral rating from JP Morgan ZD
FRESENIUS SE : Jefferies gives a Buy rating ZD
European Midday Briefing : Stocks Buoyed by Some Solid Earnings DJ
Fresenius makes strong start to the year - forecast raised thanks to subsidiary Kabi DP
Fresenius Medical beats earnings expectations, keeps outlook; shares sink RE
German healthcare group Fresenius Q1 EBIT beats expectations RE
Strabag, Porr to Buy Portions of Fresenius' Vamed Group MT
Fresenius Hikes FY24 Outlook MT
EMEA Morning Briefing : Stock Futures Mixed as Earnings in Focus DJ
Fresenius SE & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
PORR AG and Strabag SE signed a purchase agreement to acquire Vamed Engineering Gmbh from Fresenius SE & Co. KGaA for ?90 million. CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading MT
Fresenius raises forecast thanks to good business at subsidiary Kabi DP
Chart Fresenius SE & Co. KGaA
More charts
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
28.48 EUR
Average target price
36.28 EUR
Spread / Average Target
+27.39%
Consensus
  1. Stock Market
  2. Equities
  3. FRE Stock
  4. News Fresenius SE & Co. KGaA
  5. Fresenius: A strong year ending provides good momentum for 2024